EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

RBT ‐1, a “preconditioning” agent, mitigates syndecan‐1 shedding in patients undergoing “on pump” cardiac surgery and following experimental AKI

Ali C M Johnson, Richard A Zager iD

Physiological Reports · 2025

DOI: 10.14814/phy2.70218 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Physiological Reports, 2025. Verfasst von Ali C M Johnson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Renibus Therapeutics, Southlake, Texas, USA. Hauptthemen laut MEDLINE: Acute Kidney Injury, Cardiac Surgical Procedures, Postoperative Complications, Syndecan-1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Renibus Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During systemic stress, syndecan‐1 (SDC‐1) shedding into plasma results, implying endothelial damage. RBT‐1, a “preconditioning” agent, has been shown to mitigate postoperative complications following cardiac surgeries. This study assessed whether RBT‐1 preconditioning attenuated SDC‐1 shedding in these patients, implying a vascular protective effect. Patients ( n , 112) were randomized to receive low‐dose RBT‐1, high‐dose RBT‐1, or placebo 24–48 h prior to surgery. Plasma samples were obtained before and 2 days postsurgery and assayed for SDC‐1 (ELISA). To gain further insights, male CD‐1 mice were subjected to acute renal injuries, and RBT‐1's impact on plasma SDC‐1 increases, vascular/aortic stress responses (NGAL/KIM‐1/IL‐6 gene induction), and two vascular cytoprotective pathways (Nrf2; ferritin) were assessed. Baseline plasma SDC‐1 levels did not differ between patient groups. The placebo group developed an approximate 50% plasma SDC‐1 (ng/mL) increase ( p , 0.012). Conversely, no significant SDC‐1 increases were seen in the RBT‐1 treatment groups. Experimental injury markedly increased plasma SDC‐1 concentrations, and these were significantly blunted by RBT‐1 preconditioning. RBT‐1 also mitigated AKI‐induced aortic NGAL/KIM‐1/IL‐6 mRNA increases, activated aortic Nrf2, and increased vascular ferritin levels. RBT‐1 preconditioning diminishes SDC‐1 release and upregulates vascular ferritin and Nrf2. Hence, RBT‐1 preconditioning can confer select vasoprotective effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryCardiac Surgical ProceduresPostoperative ComplicationsSyndecan-1AgedAnimalsFemaleHumansMaleMiceMiddle AgedHepatitis A Virus Cellular Receptor 1Interleukin-6NF-E2-Related Factor 2

Stichwörter der Autor:innen

Nrf2acute kidney injuryendotoxemiaglycocalyxisoproterenolpreconditioningsyndecan‐1

Substanzen

Hepatitis A Virus Cellular Receptor 1Interleukin-6NF-E2-Related Factor 2SDC1 protein, humanSyndecan-1

Autor:innen und Institutionen

  • Renibus Therapeutics, Southlake, Texas, USA.
  • Fred Hutch Cancer Center, Seattle, WA, USA.
  • The University of Washington, Seattle, WA, USA.

ORCID-Profile: Richard A Zager

Förderung

  • Renibus Therapeutics

Zitieren

APA

Johnson, A. C. M., & Zager, R. A. (2025). RBT ‐1, a “preconditioning” agent, mitigates syndecan‐1 shedding in patients undergoing “on pump” cardiac surgery and following experimental AKI. Physiological Reports. https://doi.org/10.14814/phy2.70218

Vancouver

Johnson ACM, Zager RA. RBT ‐1, a “preconditioning” agent, mitigates syndecan‐1 shedding in patients undergoing “on pump” cardiac surgery and following experimental AKI. Physiological Reports. 2025. doi:10.14814/phy2.70218

BibTeX
@article{Johnson2025,
  author = {Johnson, Ali C M and Zager, Richard A},
  title = {RBT ‐1, a “preconditioning” agent, mitigates syndecan‐1 shedding in patients undergoing “on pump” cardiac surgery and following experimental AKI},
  journal = {Physiological Reports},
  year = {2025},
  doi = {10.14814/phy2.70218}
}
Kostenlos starten →